Hello. My name is Dr. Kevin Pollock from Health Protection Scotland.
I'm going to deliver a presentation on
the impact of the HPV vaccine program within the United Kingdom.
The format of this presentation will take
the listener through the following: What is the Human Papillomavirus?
How do we implement and monitor HPV infection through surveillance?
It's absolutely important to realize that vaccine uptake and high maintenance of
that vaccine uptake is integral to the success of the program.
And is with any other new vaccine program which has been implemented,
it is incredibly important to monitor adverse events as and when they arise.
It is also very important and critical to the success of
the vaccine program that we monitor the effectiveness of the vaccine.
We can do that individually and at the population level.
I will also discuss future work concerning
the program and how this may impact on cervical screening.
I will round off with some conclusions to the piece of work so far.
There are approximately 3,000 cases of
cervical cancer throughout the United Kingdom every year.
Approximately, one-third of these women will die.
Notwithstanding, the significant number of cervical abnormalities which are diagnosed
every year leading to psychological burden and mental anguish for these ladies.
If we consider cervical cancer in other parts of the world,
it's a very very serious public health problem with
approximately one death every two minutes, each year, worldwide.
Given that there are fewer screening programs and very low uptake of vaccine, if at all,
the mortality rates associated with
cervical cancer are very high in the developing world.
The main risk factors for
cervical cancer are infections with Human Papillomavirus or HPV,
tobacco smoking, and socio-economic status.